

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08a/b (06-03)

Approved for use through 07/31/2003. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number 10/049,316
Filing Date February 8, 2002
First Named Inventor
Art Unit N/A
Examiner Name Not Yet Assigned
Attorney Docket Number 7529/1F590US1

RECEIVED
AUG 1 2003
TECH-CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
mm	1	5,851,756		Steinman et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
mm	2	Blake, et al., Immunity, 7:791-802, 1997	
	3	Chen, et al., J. Gen. Virol., 80:447-455, 1999	
	4	Gutierrez, et al., J. Gen. Virol., 78:1663-70, 1997	
	5	Inaba, et al., J. Exp. Med., 188:2163-73, 1998	
	6	Khanna, et al., Eur. J. Immunol., 28:451-458, 1998	
	7	Lee, et al., Eur. J. Immunol., 26:1875-83, 1996	
	8	Levitskaya, et al., Nature, 375 685-688, 1995	
	9	Rickinson and Moss, Ann. Rev. Immunol., 15:405-31, 1997	
	10	Steinman, Exper. Hematol., 24:859-862, 1996	
	11	Steven, et al., J. Exp. Med., 184:1801-13, 1996	
	12	Yates, et al., Nature, 313:815, 1985	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	June 21, 2004
-----------------------	--	--------------------	------------------

LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO.: 7529/1F590 SERIAL NO: t/b/a/
APPLICANT: Ralph M. STEINMAN FILING DATE: Concurrently Herewith
CONFIRMATION NO:

U.S. PATENT DOCUMENTS

<u>*EXAMINER</u> <u>INITIALS</u>	<u>DOCUMENT</u> <u>NUMBER</u>	<u>DATE</u>	<u>NAME</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>FILING DATE</u>
-------------------------------------	----------------------------------	-------------	-------------	--------------	-----------------	--------------------

FOREIGN PATENT DOCUMENTS

<u>*EXAMINER</u> <u>INITIALS</u>	<u>DOCUMENT</u> <u>NUMBER</u>	<u>DATE</u>	<u>COUNTRY</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>TRANSLATION</u> <u>YES</u> <u>NO</u>
-------------------------------------	----------------------------------	-------------	----------------	--------------	-----------------	--

mm
I
1. 96 02563 A 2/01/1996 WO
2. 97 24447 A 7/10/1997 WO
3. 2,180,193 A 12/29/1996 CA

OTHER REFERENCES**(INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)**

*EXAMINER
INITIALS

mm
4. THOMSON, S.A. et al., "TARGETING A POLYPEPTIDE PROTEIN INCORPORATING A MULTIPLE CLASS II-RESTRICTED VIRAL EPITOPES TO THE SECRETORY/ENDOCYTIC PATHWAY FACILITATES IMMUNE RECOGNITION BY CD4+ CYTOTOXIC T LYMPHOCYTES: A NOVEL APPROACH TO VACCINE DESIGN", Journal of Virology, Volume 72, No. 3, March 1998, pages 2246-2252.

mm
5. KHANNA, R. et al., "TARGETING EPSTEIN-BARR VIRUS NUCLEAR ANTIGEN 1 (EBNA1) THROUGH THE CLASS II PATHWAY RESTORES IMMUNE RECOGNITION BY EBNA1 - SPECIFIC CYTOTOXIC T LYMPHOCYTES: EVIDENCE FOR HLA-DM-INDEPENDENT PROCESSING", International Immunology, Volume 9, No. 10, October 1997, pages 1537-1543.

10/049316

JC12 Rec'd 2004 JUN 03 03 03 2002

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE

SHEET 2 OF 2
(REV. 7-80)**LIST OF REFERENCES CITED BY APPLICANT**

(Use Several Sheets if Necessary)

DOCKET NO.: 7529/1F590
APPLICANT: Ralph M. STEINMANSERIAL NO: t/b/a/
FILING DATE: Concurrently Herewith
CONFIRMATION NO:*EXAMINER
INITIALS

mm 6. MURRAY, R.J. et al., "IDENTIFICATION OF TARGET ANTIGENS FOR THE HUMAN CYTOTOXIC T CELL RESPONSE TO EPSTEIN-BARR VIRUS (EBV): IMPLICATIONS FOR THE IMMUNE CONTROL OF EBV-POSITIVE MALIGNANCIES", Journal of Experimental Medicine, Volume 176, No. 1, July 1, 1992, pages 157-168.

mm 7. DI NICOLA, M. et al., "GENE TRANSFER INTO HUMAN DENDRITIC ANTIGEN-PRESENTING CELLS BY VACCINIA VIRUS AND ADENOVIRUS VECTORS", Cancer Gene Therapy, Volume 5, No. 6, November 1998, pages 350-356.


mm 8. KHANNA, R. et al., "VACCINE STRATEGIES AGAINST EPSTEIN-BARR VIRUS-ASSOCIATED DISEASES : LESSONS FROM STUDIES ON CYTOTOXIC T-CELL-MEDIATED IMMUNE REGULATION", Immunological Reviews, Vol. 170, August 1999, pages 49-64.

mm 9. TARTE, K. et al., "DENDRITIC CELL-BASED VACCINE: A PROMISING APPROACH FOR CANCER IMMUNOTHERAPY", Leukemia, Vol. 13, No. 5, May 1999, pages 653-663.

mm 10. MÜNZ, C. et al., "HUMAN CD4(+) T LYMPHOCYTES CONSISTENTLY RESPOND TO THE LATENT ePSTEIN-bARR VIRUS NUCLEAR ANTIGEN EBNA1", Journal of Experimental Medicine, Volume 191, No. 10, May 15, 2000, pages 1649-1660.

mm 11. BICKHAM, K. et al., "EBNA1-SPECIFIC CD4+ T CELLS IN HEALTHY CARRIERS OF EPSTEIN-BARR VIRUS ARE PRIMARILY TH1 IN FUNCTION", Journal of Clinical Investigation, Vol. 107, No. 1, January 2001, pages 121-130.

EXAMINER:



DATE CONSIDERED:

June 21, 2004

*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.